Outcomes in COVID-19 domperidone studies

0 0.5 1 1.5+ All studies -36% 1 173 Improvement, Studies, Patients Relative Risk Viral clearance -15% 1 173 RCTs -36% 1 173 Early -36% 1 173 Domperidone for COVID-19 c19early.org November 2025 Favorsdomperidone Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Rabanal .. (DB RCT) -36% 1.36 [0.83-2.23] no recov. 87 (n) 86 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.23 Early treatment -36% 1.36 [0.83-2.23] 87 (n) 86 (n) 36% higher risk All studies -36% 1.36 [0.83-2.23] 87 (n) 86 (n) 36% higher risk 1 domperidone COVID-19 study c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.23 Effect extraction pre-specified(most serious outcome) Favors domperidone Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Rabanal .. (DB RCT) -36% 1.36 [0.83-2.23] no recov. 87 (n) 86 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.23 Early treatment -36% 1.36 [0.83-2.23] 87 (n) 86 (n) 36% higher risk All studies -36% 1.36 [0.83-2.23] 87 (n) 86 (n) 36% higher risk 1 domperidone COVID-19 recovery result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.23 Favors domperidone Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Rabanal .. (DB RCT) -15% 1.15 [0.73-1.82] viral+ 28/87 24/86 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.55 Early treatment -15% 1.15 [0.73-1.82] 28/87 24/86 15% higher risk All studies -15% 1.15 [0.73-1.82] 28/87 24/86 15% higher risk 1 domperidone COVID-19 viral clearance result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.55 Favors domperidone Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Rabanal .. (DB RCT) -36% 1.36 [0.83-2.23] no recov. 87 (n) 86 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.23 Early treatment -36% 1.36 [0.83-2.23] 87 (n) 86 (n) 36% higher risk All studies -36% 1.36 [0.83-2.23] 87 (n) 86 (n) 36% higher risk 1 domperidone COVID-19 Randomized Controlled Trial c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.23 Effect extraction pre-specified(most serious outcome) Favors domperidone Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Rabanal .. (DB RCT) -36% 1.36 [0.83-2.23] no recov. 87 (n) 86 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.23 Early treatment -36% 1.36 [0.83-2.23] 87 (n) 86 (n) 36% higher risk All studies -36% 1.36 [0.83-2.23] 87 (n) 86 (n) 36% higher risk 1 domperidone COVID-19 peer reviewed studies c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.23 Effect extraction pre-specified(most serious outcome) Favors domperidone Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Rabanal .. (DB RCT) -36% 1.36 [0.83-2.23] no recov. 87 (n) 86 (n) Improvement, RR [CI] Treatment Control Rabanal .. (DB RCT) 67% 0.33 [0.01-8.04] no recov. 0/87 1/86 Rabanal .. (DB RCT) -98% 1.98 [0.78-5.03] no recov. 12/87 6/86 Rabanal .. (DB RCT) -398% 4.98 [0.24-102] no recov. 2/87 0/86 Rabanal .. (DB RCT) 67% 0.33 [0.01-8.04] no recov. 0/87 1/86 Rabanal .. (DB RCT) -199% 2.99 [0.12-72.4] no recov. 1/87 0/86 Rabanal .. (DB RCT) -199% 2.99 [0.12-72.4] no recov. 1/87 0/86 Rabanal .. (DB RCT) -197% 2.97 [0.31-28.0] no recov. 3/87 1/86 Rabanal .. (DB RCT) -98% 1.98 [0.18-21.4] no recov. 2/87 1/86 Rabanal .. (DB RCT) 67% 0.33 [0.01-8.04] no recov. 0/87 1/86 Rabanal .. (DB RCT) 51% 0.49 [0.05-5.35] no recov. 1/87 2/86 Rabanal .. (DB RCT) -98% 1.98 [0.18-21.4] no recov. 2/87 1/86 Rabanal .. (DB RCT) 80% 0.20 [0.01-4.09] no recov. 0/87 2/86 Rabanal .. (DB RCT) -15% 1.15 [0.40-3.29] no recov. 7/87 6/86 Rabanal .. (DB RCT) -98% 1.98 [0.18-21.4] no recov. 2/87 1/86 Rabanal .. (DB RCT) -197% 2.97 [0.31-28.0] no recov. 3/87 1/86 Rabanal .. (DB RCT) 67% 0.33 [0.01-8.04] no recov. 0/87 1/86 Rabanal .. (DB RCT) 67% 0.33 [0.01-8.04] no recov. 0/87 1/86 Rabanal .. (DB RCT) -15% 1.15 [0.73-1.82] viral+ 28/87 24/86 Domperidone COVID-19 outcomes c19early.org November 2025 Favors domperidone Favors control